{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:57:36Z","timestamp":1787795856984,"version":"build-2784847793"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Area of Excellence Scheme of the University Grants Committee, Hong Kong","award":["AoE\/M-12\/06"],"award-info":[{"award-number":["AoE\/M-12\/06"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.addr.2016.04.013","type":"journal-article","created":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T02:48:41Z","timestamp":1462070921000},"page":"21-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis"],"prefix":"10.1016","volume":"102","author":[{"given":"Dede K.W.","family":"Man","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Y.T.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Casettari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Gonzalez-Juarrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny K.W.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2016.04.013_bb0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/CLEP.S35839","article-title":"Extensively drug-resistant tuberculosis: epidemiology and management","volume":"6","author":"Matteelli","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.addr.2016.04.013_bb0010","series-title":"Definitions and Reporting Framework for Tuberculosis - 2013 Revision","author":"WHO","year":"2013"},{"issue":"2","key":"10.1016\/j.addr.2016.04.013_bb0015","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1378\/chest.08-2427","article-title":"Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran","volume":"136","author":"Velayati","year":"2009","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40265-014-0331-4","article-title":"Delamanid: a review of its use in patients with multidrug-resistant tuberculosis","volume":"75","author":"Blair","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2016.04.013_bb0025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2147\/IDR.S68351","article-title":"New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid","volume":"8","author":"Brigden","year":"2015","journal-title":"Infect. Drug Resist."},{"issue":"15","key":"10.1016\/j.addr.2016.04.013_bb0030","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1517\/14656566.2015.1080240","article-title":"Bedaquiline and delamanid in tuberculosis","volume":"16","author":"Esposito","year":"2015","journal-title":"Expert. Opin. Pharmacother."},{"issue":"5","key":"10.1016\/j.addr.2016.04.013_bb0035","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrd3975","article-title":"Platforms for antibiotic discovery","volume":"12","author":"Lewis","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.addr.2016.04.013_bb0040","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1166\/jbn.2014.1929","article-title":"RNA interference-based therapeutics: molecular platforms for infectious diseases","volume":"10","author":"Dyawanapelly","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"issue":"2","key":"10.1016\/j.addr.2016.04.013_bb0045","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/ph6020223","article-title":"RNAi therapeutic platforms for lung diseases","volume":"6","author":"Fujita","year":"2013","journal-title":"Pharmaceuticals"},{"issue":"12","key":"10.1016\/j.addr.2016.04.013_bb0050","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nchembio839","article-title":"RNAi therapeutics: a potential new class of pharmaceutical drugs","volume":"2","author":"Bumcrot","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.addr.2016.04.013_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther.\u2013Nucleic Acids"},{"issue":"3","key":"10.1016\/j.addr.2016.04.013_bb0060","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.antiviral.2007.11.009","article-title":"Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)","volume":"77","author":"DeVincenzo","year":"2008","journal-title":"Antivir. Res."},{"issue":"19","key":"10.1016\/j.addr.2016.04.013_bb0065","doi-asserted-by":"crossref","first-page":"8800","DOI":"10.1073\/pnas.0912186107","article-title":"A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus","volume":"107","author":"DeVincenzo","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.addr.2016.04.013_bb0070","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1164\/rccm.201003-0422OC","article-title":"RNA interference therapy in lung transplant patients infected with respiratory syncytial virus","volume":"183","author":"Zamora","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.addr.2016.04.013_bb0075","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/mt.2012.107","article-title":"Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes","volume":"20","author":"Chandra","year":"2012","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.addr.2016.04.013_bb0080","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1086\/504267","article-title":"Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference","volume":"193","author":"Geisbert","year":"2006","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/jac\/dki416","article-title":"Effects of short interfering RNA against methicillin-resistant Staphylococcus aureus coagulase in vitro and in vivo","volume":"57","author":"Yanagihara","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.addr.2016.04.013_bb0090","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/11318190-000000000-00000","article-title":"RNA interference technologies and therapeutics: from basic research to products","volume":"23","author":"Lopez-Fraga","year":"2009","journal-title":"BioDrugs"},{"issue":"4","key":"10.1016\/j.addr.2016.04.013_bb0095","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","article-title":"RNA interference: biology, mechanism, and applications","volume":"67","author":"Agrawal","year":"2003","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0100","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cell.2009.09.013","article-title":"Regulating the regulators: posttranslational modifications of RNA silencing factors","volume":"139","author":"Heo","year":"2009","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrm2085","article-title":"Illuminating the silence: understanding the structure and function of small RNAs","volume":"8","author":"Rana","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0110","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.sbi.2009.12.001","article-title":"Structural insights into RNA interference","volume":"20","author":"Sashital","year":"2010","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"2","key":"10.1016\/j.addr.2016.04.013_bb0115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.gene.2013.12.019","article-title":"Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies","volume":"538","author":"Deng","year":"2014","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.addr.2016.04.013_bb0120","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrg2006","article-title":"Strategies for silencing human disease using RNA interference","volume":"8","author":"Kim","year":"2007","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nrc2966","article-title":"RNA interference in the clinic: challenges and future directions","volume":"11","author":"Pecot","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"18","key":"10.1016\/j.addr.2016.04.013_bb0130","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1158\/0008-5472.CAN-10-2010","article-title":"The promise of microRNA replacement therapy","volume":"70","author":"Bader","year":"2010","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.addr.2016.04.013_bb0135","doi-asserted-by":"crossref","first-page":"851","DOI":"10.15252\/emmm.201100899","article-title":"Development of microRNA therapeutics is coming of age","volume":"6","author":"van Rooij","year":"2014","journal-title":"EMBO Mol. Med."},{"issue":"9","key":"10.1016\/j.addr.2016.04.013_bb0140","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"9911","key":"10.1016\/j.addr.2016.04.013_bb0145","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.addr.2016.04.013_bb0150","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/mt.2009.273","article-title":"First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder","volume":"18","author":"Leachman","year":"2010","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.addr.2016.04.013_bb0155","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/eye.2012.106","article-title":"Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients","volume":"26","author":"Nguyen","year":"2012","journal-title":"Eye"},{"issue":"36","key":"10.1016\/j.addr.2016.04.013_bb0160","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1200\/JCO.2013.55.0376","article-title":"First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors","volume":"32","author":"Schultheis","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.addr.2016.04.013_bb0165","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","article-title":"First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement","volume":"3","author":"Tabernero","year":"2013","journal-title":"Can. Dis."},{"key":"10.1016\/j.addr.2016.04.013_bb0170","author":"Complete results of our ALN-RSV01 phase IIb study"},{"issue":"8","key":"10.1016\/j.addr.2016.04.013_bb0175","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nrd4696","article-title":"Towards host-directed therapies for tuberculosis","volume":"14","author":"Zumla","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0180","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/imr.12255","article-title":"New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics","volume":"264","author":"Hawn","year":"2015","journal-title":"Immunol. Rev."},{"issue":"9","key":"10.1016\/j.addr.2016.04.013_bb0185","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/cid\/civ631","article-title":"Host-directed therapies for tackling multi-drug resistant tuberculosis: learning from the Pasteur\u2013Bechamp Debates","volume":"61","author":"Zumla","year":"2015","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.addr.2016.04.013_bb0190","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.4049\/jimmunol.1201538","article-title":"Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages","volume":"189","author":"Bruns","year":"2012","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.addr.2016.04.013_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017091","article-title":"Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice","volume":"6","author":"Koo","year":"2011","journal-title":"PloS ONE"},{"issue":"5","key":"10.1016\/j.addr.2016.04.013_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004917","article-title":"Neutrophil-derived MMP-8 drives AMPK-dependent matrix destruction in human pulmonary tuberculosis","volume":"11","author":"Ong","year":"2015","journal-title":"PLoS Pathog."},{"issue":"9","key":"10.1016\/j.addr.2016.04.013_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002262","article-title":"Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs","volume":"7","author":"Subbian","year":"2011","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0210","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ajpath.2011.03.039","article-title":"Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology","volume":"179","author":"Subbian","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.addr.2016.04.013_bb0215","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S1473-3099(16)00070-0","article-title":"Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers","volume":"16","author":"Wallis","year":"2016","journal-title":"Lancet Infect. Dis."},{"issue":"51","key":"10.1016\/j.addr.2016.04.013_bb0220","doi-asserted-by":"crossref","first-page":"35941","DOI":"10.1074\/jbc.M804543200","article-title":"Abl kinases regulate autophagy by promoting the trafficking and function of lysosomal components","volume":"283","author":"Yogalingam","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.addr.2016.04.013_bb0225","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.chembiol.2009.04.001","article-title":"Mycolic acid cyclopropanation is essential for viability, drug resistance, and cell wall integrity of Mycobacterium tuberculosis","volume":"16","author":"Barkan","year":"2009","journal-title":"Chem. Biol."},{"issue":"1\u20132","key":"10.1016\/j.addr.2016.04.013_bb0230","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1574-6968.1994.tb07194.x","article-title":"Mycobacterial cell wall: structure and role in natural resistance to antibiotics","volume":"123","author":"Jarlier","year":"1994","journal-title":"FEMS Microbiol. Lett."},{"issue":"4","key":"10.1016\/j.addr.2016.04.013_bb0235","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1128\/MMBR.00032-13","article-title":"Host-directed therapeutics for tuberculosis: can we harness the host?","volume":"77","author":"Hawn","year":"2013","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"8","key":"10.1016\/j.addr.2016.04.013_bb0240","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tips.2015.05.005","article-title":"Exploring the potential of adjunct therapy in tuberculosis","volume":"36","author":"Rayasam","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.addr.2016.04.013_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000839","article-title":"Identification of host-dependent survival factors for intracellular Mycobacterium tuberculosis through an siRNA screen","volume":"6","author":"Jayaswal","year":"2010","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0250","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tube.2010.11.004","article-title":"Local pulmonary immunotherapy with siRNA targeting TGFbeta1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice","volume":"91","author":"Rosas-Taraco","year":"2011","journal-title":"Tuberculosis"},{"issue":"2","key":"10.1016\/j.addr.2016.04.013_bb0255","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1165\/rcmb.2008-0363OC","article-title":"Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis","volume":"41","author":"Rosas-Taraco","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"4","key":"10.1016\/j.addr.2016.04.013_bb0260","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.bbagen.2007.12.010","article-title":"Inhibition of bfl-1\/A1 by siRNA inhibits mycobacterial growth in THP-1 cells by enhancing phagosomal acidification","volume":"1780","author":"Dhiman","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.addr.2016.04.013_bb0265","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bbagen.2006.11.016","article-title":"Differential expression of NF-kappaB in mycobacteria infected THP-1 affects apoptosis","volume":"1770","author":"Dhiman","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.addr.2016.04.013_bb0270","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.biocel.2010.12.014","article-title":"Bfl-1\/A1 acts as a negative regulator of autophagy in mycobacteria infected macrophages","volume":"43","author":"Kathania","year":"2011","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"7","key":"10.1016\/j.addr.2016.04.013_bb0275","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1083\/jcb.200603026","article-title":"Higher order Rab programming in phagolysosome biogenesis","volume":"174","author":"Roberts","year":"2006","journal-title":"J. Cell Biol."},{"issue":"10","key":"10.1016\/j.addr.2016.04.013_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003697","article-title":"MicroRNA-155 promotes autophagy to eliminate intracellular mycobacteria by targeting Rheb","volume":"9","author":"Wang","year":"2013","journal-title":"PLoS Pathog."},{"issue":"11","key":"10.1016\/j.addr.2016.04.013_bb0285","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.4049\/jimmunol.1402557","article-title":"MicroRNA-125a inhibits autophagy activation and antimicrobial responses during mycobacterial infection","volume":"194","author":"Kim","year":"2015","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.addr.2016.04.013_bb0290","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1462-5822.2006.00705.x","article-title":"Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host defence mechanism","volume":"8","author":"Deretic","year":"2006","journal-title":"Cell. Microbiol."},{"issue":"5","key":"10.1016\/j.addr.2016.04.013_bb0295","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.femsre.2005.04.013","article-title":"Mycobacterial manipulation of the host cell","volume":"29","author":"Hestvik","year":"2005","journal-title":"FEMS Microbiol. Rev."},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0300","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.coi.2010.10.010","article-title":"Role of autophagy in the host response to microbial infection and potential for therapy","volume":"23","author":"Fabri","year":"2011","journal-title":"Curr. Opin. Immunol."},{"issue":"6","key":"10.1016\/j.addr.2016.04.013_bb0305","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cell.2004.11.038","article-title":"Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages","volume":"119","author":"Gutierrez","year":"2004","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.addr.2016.04.013_bb0310","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1247\/csf.27.421","article-title":"Autophagosome formation in mammalian cells","volume":"27","author":"Mizushima","year":"2002","journal-title":"Cell Struct. Funct."},{"issue":"10","key":"10.1016\/j.addr.2016.04.013_bb0315","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nri2161","article-title":"Unveiling the roles of autophagy in innate and adaptive immunity","volume":"7","author":"Levine","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"16","key":"10.1016\/j.addr.2016.04.013_bb0320","doi-asserted-by":"crossref","first-page":"15485","DOI":"10.1074\/jbc.R500003200","article-title":"Structural clues to Rab GTPase functional diversity","volume":"280","author":"Pfeffer","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"20","key":"10.1016\/j.addr.2016.04.013_bb0325","doi-asserted-by":"crossref","first-page":"13326","DOI":"10.1074\/jbc.272.20.13326","article-title":"Arrest of mycobacterial phagosome maturation is caused by a block in vesicle fusion between stages controlled by rab5 and rab7","volume":"272","author":"Via","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2016.04.013_bb0330","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev-immunol-020711-075013","article-title":"microRNA regulation of inflammatory responses","volume":"30","author":"O'Connell","year":"2012","journal-title":"Annu. Rev. Immunol."},{"issue":"7583","key":"10.1016\/j.addr.2016.04.013_bb0335","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nature16451","article-title":"Unique role for ATG5 in neutrophil-mediated immunopathology during M. tuberculosis infection","volume":"528","author":"Kimmey","year":"2015","journal-title":"Nature"},{"issue":"7583","key":"10.1016\/j.addr.2016.04.013_bb0340","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature16324","article-title":"Tuberculosis: autophagy is not the answer","volume":"528","author":"Behar","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.addr.2016.04.013_bb0345","doi-asserted-by":"crossref","first-page":"139127","DOI":"10.1155\/2012\/139127","article-title":"The tuberculous granuloma: an unsuccessful host defence mechanism providing a safety shelter for the bacteria?","volume":"2012","author":"Silva Miranda","year":"2012","journal-title":"Clin. Dev. Immunol."},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0350","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2008.11.014","article-title":"The role of the granuloma in expansion and dissemination of early tuberculous infection","volume":"136","author":"Davis","year":"2009","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.addr.2016.04.013_bb0355","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/430914","article-title":"Reconsidering adjuvant immunotherapy for tuberculosis","volume":"41","author":"Wallis","year":"2005","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.addr.2016.04.013_bb0360","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1189\/jlb.0607426","article-title":"XCL1 (lymphotactin) chemokine produced by activated CD8 T cells during the chronic stage of infection with Mycobacterium tuberculosis negatively affects production of IFN-gamma by CD4 T cells and participates in granuloma stability","volume":"82","author":"Ordway","year":"2007","journal-title":"J. Leukoc. Biol."},{"issue":"5","key":"10.1016\/j.addr.2016.04.013_bb0365","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1128\/IAI.72.5.2628-2634.2004","article-title":"Down-modulation of lung immune responses by interleukin-10 and transforming growth factor (TGF-) and analysis of TGF- receptors I and II in active tuberculosis. Infection and","volume":"72","author":"Bonecini-Almeida","year":"2004","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.addr.2016.04.013_bb0370","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.4049\/jimmunol.178.5.2661","article-title":"Cutting edge: regulatory T cells prevent efficient clearance of Mycobacterium tuberculosis","volume":"178","author":"Kursar","year":"2007","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.addr.2016.04.013_bb0375","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.4049\/jimmunol.169.11.6343","article-title":"In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL\/6 mice","volume":"169","author":"Turner","year":"2002","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.addr.2016.04.013_bb0380","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.smim.2014.09.010","article-title":"Macrophage immunoregulatory pathways in tuberculosis","volume":"26","author":"Rajaram","year":"2014","journal-title":"Semin. Immunol."},{"issue":"8","key":"10.1016\/j.addr.2016.04.013_bb0385","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1002\/eji.201040433","article-title":"Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung","volume":"40","author":"Redford","year":"2010","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.addr.2016.04.013_bb0390","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/mi.2011.7","article-title":"The role of IL-10 in immune regulation during M. tuberculosis infection","volume":"4","author":"Redford","year":"2011","journal-title":"Mucosal Immunol."},{"issue":"7507","key":"10.1016\/j.addr.2016.04.013_bb0395","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature13489","article-title":"Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk","volume":"511","author":"Mayer-Barber","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0400","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/imr.12249","article-title":"Cytokine and lipid mediator networks in tuberculosis","volume":"264","author":"Mayer-Barber","year":"2015","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.addr.2016.04.013_bb0405","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.immuni.2011.12.002","article-title":"Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection","volume":"35","author":"Mayer-Barber","year":"2011","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.addr.2016.04.013_bb0410","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.4049\/jimmunol.0904189","article-title":"Caspase-1 independent IL-1beta production is critical for host resistance to mycobacterium tuberculosis and does not require TLR signaling in vivo","volume":"184","author":"Mayer-Barber","year":"2010","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0415","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tube.2010.08.009","article-title":"Inhaled drug therapy for treatment of tuberculosis","volume":"91","author":"Misra","year":"2011","journal-title":"Tuberculosis"},{"issue":"2","key":"10.1016\/j.addr.2016.04.013_bb0420","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ijpharm.2014.12.009","article-title":"Pulmonary drug delivery systems for tuberculosis treatment","volume":"478","author":"Pham","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2016.04.013_bb0425","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jconrel.2014.05.055","article-title":"Major degradable polycations as carriers for DNA and siRNA","volume":"193","author":"Islam","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2016.04.013_bb0430","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.addr.2014.05.018","article-title":"siRNA delivery to the lung: what's new?","volume":"75","author":"Merkel","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0435","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/bc200296q","article-title":"Pulmonary gene delivery using polymeric nonviral vectors","volume":"23","author":"Merkel","year":"2012","journal-title":"Bioconjug. Chem."},{"issue":"6 Pt 3","key":"10.1016\/j.addr.2016.04.013_bb0440","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.biotechadv.2015.04.008","article-title":"Achieving successful delivery of oligonucleotides\u2014from physico-chemical characterization to in vivo evaluation","volume":"33","author":"Scomparin","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.addr.2016.04.013_bb0445","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1146\/annurev-bioeng-071813-105119","article-title":"Recent advances in nanoparticle-mediated siRNA delivery","volume":"16","author":"Williford","year":"2014","journal-title":"Annu. Rev. Biomed. Eng."},{"issue":"8","key":"10.1016\/j.addr.2016.04.013_bb0450","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"issue":"2","key":"10.1016\/j.addr.2016.04.013_bb0455","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090338","article-title":"Development of pre-clinical models for evaluating the therapeutic potential of candidate siRNA targeting STAT6","volume":"9","author":"Healey","year":"2014","journal-title":"PloS ONE"},{"issue":"2","key":"10.1016\/j.addr.2016.04.013_bb0460","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1183\/09031936.00181312","article-title":"Targeting cell motility in pulmonary arterial hypertension","volume":"43","author":"Paulin","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"31","key":"10.1016\/j.addr.2016.04.013_bb0465","doi-asserted-by":"crossref","first-page":"7744","DOI":"10.1016\/j.biomaterials.2013.06.041","article-title":"In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models","volume":"34","author":"Conde","year":"2013","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.addr.2016.04.013_bb0470","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2013.04.018","article-title":"Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA","volume":"171","author":"Taratula","year":"2013","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.addr.2016.04.013_bb0475","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/mt.2013.10","article-title":"Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes","volume":"21","author":"Shim","year":"2013","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.addr.2016.04.013_bb0480","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1248\/bpb.b13-00167","article-title":"Gene silencing in a mouse lung metastasis model by an inhalable dry small interfering RNA powder prepared using the supercritical carbon dioxide technique","volume":"36","author":"Okuda","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.addr.2016.04.013_bb0485","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jconrel.2015.08.030","article-title":"Hybrid pulmonary surfactant-coated nanogels mediate efficient in vivo delivery of siRNA to murine alveolar macrophages","volume":"217","author":"De Backer","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2016.04.013_bb0490","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jconrel.2013.12.008","article-title":"Combined delivery of HMGB-1 box a peptide and S1PLyase siRNA in animal models of acute lung injury","volume":"175","author":"Oh","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2016.04.013_bb0495","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jconrel.2015.02.016","article-title":"Selective targeting of alveolar type II respiratory epithelial cells by anti-surfactant protein-C antibody-conjugated lipoplexes","volume":"203","author":"Wu","year":"2015","journal-title":"J. Control. Release"},{"issue":"17","key":"10.1016\/j.addr.2016.04.013_bb0500","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1007\/s00018-009-0053-z","article-title":"Nanocarriers' entry into the cell: relevance to drug delivery","volume":"66","author":"Hillaireau","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"issue":"16","key":"10.1016\/j.addr.2016.04.013_bb0505","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1073\/pnas.92.16.7297","article-title":"A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine","volume":"92","author":"Boussif","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.addr.2016.04.013_bb0510","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1021\/bc980148w","article-title":"Structure\u2013activity relationships of water-soluble cationic methacrylate\/methacrylamide polymers for nonviral gene delivery","volume":"10","author":"van de Wetering","year":"1999","journal-title":"Bioconjug. Chem."},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0515","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1021\/bm034041+","article-title":"Endosomal escape of polymeric gene delivery complexes is not always enhanced by polymers buffering at low pH","volume":"5","author":"Funhoff","year":"2004","journal-title":"Biomacromolecules"},{"issue":"4","key":"10.1016\/j.addr.2016.04.013_bb0520","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/09205063.2012.690282","article-title":"Modeling the proton sponge hypothesis: examining proton sponge effectiveness for enhancing intracellular gene delivery through multiscale modeling","volume":"24","author":"Freeman","year":"2013","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.addr.2016.04.013_bb0525","series-title":"Molecular Regulation of Endocytosis","first-page":"421","article-title":"Endosomal escape pathways for non-viral nucleic acid delivery systems","author":"Liang","year":"2012"},{"issue":"8","key":"10.1016\/j.addr.2016.04.013_bb0530","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1034\/j.1600-0854.2000.010803.x","article-title":"Membrane fusion mechanisms: the influenza hemagglutinin paradigm and its implications for intracellular fusion","volume":"1","author":"Stegmann","year":"2000","journal-title":"Traffic"},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0535","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/btpr.310","article-title":"Multifunctional siRNA delivery system: polyelectrolyte complex micelles of six-arm PEG conjugate of siRNA and cell penetrating peptide with crosslinked fusogenic peptide","volume":"26","author":"Choi","year":"2010","journal-title":"Biotechnol. Prog."},{"issue":"2","key":"10.1016\/j.addr.2016.04.013_bb0540","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2009.06.008","article-title":"A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo","volume":"139","author":"Hatakeyama","year":"2009","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.addr.2016.04.013_bb0545","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jconrel.2011.11.024","article-title":"Effective endogenous gene silencing mediated by pH responsive peptides proceeds via multiple pathways","volume":"158","author":"Lam","year":"2012","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.addr.2016.04.013_bb0550","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/mt.2013.54","article-title":"Endocytosis of gene delivery vectors: from clathrin-dependent to lipid raft-mediated endocytosis","volume":"21","author":"El-Sayed","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2016.04.013_bb0555","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejps.2015.03.021","article-title":"Development of a simple, biocompatible and cost-effective inulin-diethylenetriamine based siRNA delivery system","volume":"75","author":"Sardo","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2011.02.006","article-title":"Pulmonary delivery of therapeutic siRNA","volume":"64","author":"Lam","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1\u20132","key":"10.1016\/j.addr.2016.04.013_bb0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.03.017","article-title":"Formulation strategy and use of excipients in pulmonary drug delivery","volume":"392","author":"Pilcer","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.addr.2016.04.013_bb0570","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2008.09.008","article-title":"Barrier properties of mucus","volume":"61","author":"Cone","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.addr.2016.04.013_bb0575","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2016.04.013_bb0580","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pupt.2015.07.003","article-title":"Nanocomplexes for gene therapy of respiratory diseases: targeting and overcoming the mucus barrier","volume":"34","author":"Di Gioia","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.addr.2016.04.013_bb0585","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jconrel.2011.12.004","article-title":"Controlled pulmonary drug and gene delivery using polymeric nano-carriers","volume":"161","author":"Beck-Broichsitter","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2016.04.013_bb0590","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ejpb.2015.01.022","article-title":"Nano-carrier systems: strategies to overcome the mucus gel barrier","volume":"96","author":"Dunnhaupt","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"14","key":"10.1016\/j.addr.2016.04.013_bb0595","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/anie.201208556","article-title":"Use of single-site-functionalized PEG dendrons to prepare gene vectors that penetrate human mucus barriers","volume":"52","author":"Kim","year":"2013","journal-title":"Angew. Chem."},{"key":"10.1016\/j.addr.2016.04.013_bb0600","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jconrel.2014.01.007","article-title":"Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier","volume":"178","author":"Suk","year":"2014","journal-title":"J. Control. Release"},{"issue":"Pt A","key":"10.1016\/j.addr.2016.04.013_bb0605","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejpb.2015.02.014","article-title":"Barrier or carrier? Pulmonary surfactant and drug delivery","volume":"95","author":"Hidalgo","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2016.04.013_bb0610","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12931-014-0132-z","article-title":"Small interfering RNA against CD86 during allergen challenge blocks experimental allergic asthma","volume":"15","author":"Asai-Tajiri","year":"2014","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0615","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nm1164","article-title":"Inhibition of respiratory viruses by nasally administered siRNA","volume":"11","author":"Bitko","year":"2005","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.addr.2016.04.013_bb0620","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1165\/rcmb.2011-0158OC","article-title":"Development and preclinical efficacy of novel transforming growth factor-beta1 short interfering RNAs for pulmonary fibrosis","volume":"46","author":"D'Alessandro-Gabazza","year":"2012","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"5","key":"10.1016\/j.addr.2016.04.013_bb0625","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.4049\/jimmunol.1202416","article-title":"Receptor-interacting protein 2 gene silencing attenuates allergic airway inflammation","volume":"191","author":"Goh","year":"2013","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.addr.2016.04.013_bb0630","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1089\/hum.2013.142","article-title":"Small interfering RNAs targeted to interleukin-4 and respiratory syncytial virus reduce airway inflammation in a mouse model of virus-induced asthma exacerbation","volume":"25","author":"Khaitov","year":"2014","journal-title":"Hum. Gene Ther."},{"issue":"6","key":"10.1016\/j.addr.2016.04.013_bb0635","doi-asserted-by":"crossref","first-page":"L908","DOI":"10.1152\/ajplung.00115.2011","article-title":"Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 attenuates allergic asthma in mice","volume":"301","author":"Miyamoto","year":"2011","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"4","key":"10.1016\/j.addr.2016.04.013_bb0640","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/thx.2009.119974","article-title":"Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis","volume":"65","author":"Senoo","year":"2010","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.addr.2016.04.013_bb0645","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1093\/nar\/gkp106","article-title":"A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity","volume":"37","author":"Bramsen","year":"2009","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.addr.2016.04.013_bb0650","first-page":"158","article-title":"Chemical modification of siRNA","volume":"12","author":"Chernolovskaya","year":"2010","journal-title":"Curr. Opin. Mol. Ther."},{"issue":"5","key":"10.1016\/j.addr.2016.04.013_bb0655","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1039\/b918869j","article-title":"Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo","volume":"6","author":"Laursen","year":"2010","journal-title":"Mol. BioSyst."},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0660","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bmc.2007.09.019","article-title":"Synthesis of 2\u2032-O-modified adenosine building blocks and application for RNA interference","volume":"16","author":"Odadzic","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.addr.2016.04.013_bb0665","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/cbdv.200900343","article-title":"Locked nucleic acids: promising nucleic acid analogs for therapeutic applications","volume":"7","author":"Veedu","year":"2010","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.addr.2016.04.013_bb0670","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jconrel.2015.03.015","article-title":"Bio-inspired pulmonary surfactant-modified nanogels: a promising siRNA delivery system","volume":"206","author":"De Backer","year":"2015","journal-title":"J. Control. Release"},{"issue":"27","key":"10.1016\/j.addr.2016.04.013_bb0675","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.2174\/1381612821666150820105916","article-title":"Dry powder formulation of plasmid DNA and siRNA for inhalation","volume":"21","author":"Chow","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.addr.2016.04.013_bb0680","series-title":"Aerodynamic Assessment for Inhalation Products: Fundamentals and Current Pharmacopoeial Methods","first-page":"91","article-title":"Inhalation drug delivery: techniques and products","author":"Buttini","year":"2013"},{"issue":"12","key":"10.1016\/j.addr.2016.04.013_bb0685","first-page":"1406","article-title":"Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol","volume":"47","author":"Dhand","year":"2002","journal-title":"Respir. Care"},{"issue":"1\u20132","key":"10.1016\/j.addr.2016.04.013_bb0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2004.06.018","article-title":"A review of the development of Respimat Soft Mist Inhaler","volume":"283","author":"Dalby","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2016.04.013_bb0695","first-page":"145","article-title":"Development of Respimat\u00ae Soft Mist Inhaler and its clinical utility in respiratory disorders","volume":"4","author":"Dalby","year":"2011","journal-title":"Med. Device"},{"issue":"3","key":"10.1016\/j.addr.2016.04.013_bb0700","first-page":"318","article-title":"In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates","volume":"3","author":"Feddah","year":"2000","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.addr.2016.04.013_bb0705","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1208\/s12249-015-0317-x","article-title":"Devices for dry powder drug delivery to the lung","volume":"16","author":"Berkenfeld","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2016.04.013_bb0710","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.addr.2014.04.004","article-title":"Technological and practical challenges of dry powder inhalers and formulations","volume":"75","author":"Hoppentocht","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1\u20132","key":"10.1016\/j.addr.2016.04.013_bb0715","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-5173(94)90070-1","article-title":"Drug-delivery to the respiratory-tract using dry powder inhalers","volume":"101","author":"Timsina","year":"1994","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.addr.2016.04.013_bb0720","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijpharm.2006.10.028","article-title":"Influence of carrier on the performance of dry powder inhalers","volume":"334","author":"Saint-Lorant","year":"2007","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.addr.2016.04.013_bb0725","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1021\/mp500745v","article-title":"Inhalable dry powder formulations of siRNA and pH-responsive peptides with antiviral activity against H1N1 influenza virus","volume":"12","author":"Liang","year":"2015","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.addr.2016.04.013_bb0730","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1208\/s12249-012-9822-3","article-title":"Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs)","volume":"13","author":"Riley","year":"2012","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0735","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2011.08.011","article-title":"Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA","volume":"157","author":"Jensen","year":"2012","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0740","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2009.10.010","article-title":"Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation","volume":"142","author":"Jensen","year":"2010","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.addr.2016.04.013_bb0745","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejpb.2013.05.006","article-title":"Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids","volume":"86","author":"Liang","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2016.04.013_bb0750","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1465-9921-7-118","article-title":"Tuberculosis chemotherapy: current drug delivery approaches","volume":"7","author":"du Toit","year":"2006","journal-title":"Respir. Res."},{"issue":"14","key":"10.1016\/j.addr.2016.04.013_bb0755","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1001\/jama.2011.436","article-title":"Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the study C randomized controlled trial","volume":"305","author":"Lienhardt","year":"2011","journal-title":"J. Am. Med. Assoc."},{"issue":"3","key":"10.1016\/j.addr.2016.04.013_bb0760","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1208\/s12248-012-9378-x","article-title":"Challenges and opportunities in achieving bioequivalence for fixed-dose combination products","volume":"14","author":"Mitra","year":"2012","journal-title":"AAPS J."},{"issue":"11","key":"10.1016\/j.addr.2016.04.013_bb0765","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1021\/nn4047925","article-title":"Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment","volume":"7","author":"Deng","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2016.04.013_bb0770","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fphar.2014.00077","article-title":"Multifunctional polymeric micelles for delivery of drugs and siRNA","volume":"5","author":"Jhaveri","year":"2014","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.addr.2016.04.013_bb0775","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1021\/mp100460h","article-title":"Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs","volume":"8","author":"Kim","year":"2011","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.addr.2016.04.013_bb0780","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/mt.2013.120","article-title":"Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC","volume":"21","author":"Zhang","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2016.04.013_bb0785","first-page":"4441","article-title":"Novel targeting of PEGylated liposomes for codelivery of TGF-beta1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study","volume":"9","author":"Niu","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"issue":"4","key":"10.1016\/j.addr.2016.04.013_bb0790","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijantimicag.2005.07.012","article-title":"Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis","volume":"26","author":"Ahmad","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"3","key":"10.1016\/j.addr.2016.04.013_bb0795","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3109\/10717544.2014.920428","article-title":"Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs","volume":"23","author":"Kaur","year":"2016","journal-title":"Drug Deliv."},{"issue":"4","key":"10.1016\/j.addr.2016.04.013_bb0800","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.tube.2004.11.003","article-title":"Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis","volume":"85","author":"Pandey","year":"2005","journal-title":"Tuberculosis"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X16301223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X16301223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T04:25:59Z","timestamp":1718511959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X16301223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":160,"alternative-id":["S0169409X16301223"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2016.04.013","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2016.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}